Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Richter

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
JOP : Journal of the Pancreas|March 9, 2010
Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010Joshua Richter, Muhammad Wasif Saif
JOP : Journal of the Pancreas|March 9, 2010
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010Joshua Richter, Muhammad Wasif Saif
Clinical Immunology (Orlando, Fla.)|January 15, 2011
Harnessing natural killer T (NKT) cells in human myeloma: progress and challengesMadhav V Dhodapkar, Joshua Richter
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple MyelomaAmy E Pierre, Joshua Richter
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
Oncology (Williston Park, N.Y.)|June 20, 2024
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative TrialsZachary M Avigan, Joshua Richter Md
Seminars in Oncology|May 25, 2020
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to dateJoshua Richter, Larysa Sanchez, Santiago Thibaud
The Oncologist|April 9, 2026
Comment on "How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes"Joshua Richter, Michael Davis, Yi Chai
Future Oncology (London, England)|June 9, 2020
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myelomaShambavi Richard, Joshua Richter, Sundar Jagannath
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology CentersJoshua Richter, Stephen J Noga, Robert Rifkin
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
JOP : Journal of the Pancreas|March 9, 2010
Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010Joshua Richter, Muhammad Wasif Saif
JOP : Journal of the Pancreas|March 9, 2010
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010Joshua Richter, Muhammad Wasif Saif
Clinical Immunology (Orlando, Fla.)|January 15, 2011
Harnessing natural killer T (NKT) cells in human myeloma: progress and challengesMadhav V Dhodapkar, Joshua Richter
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple MyelomaAmy E Pierre, Joshua Richter
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
Oncology (Williston Park, N.Y.)|June 20, 2024
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative TrialsZachary M Avigan, Joshua Richter Md
Seminars in Oncology|May 25, 2020
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to dateJoshua Richter, Larysa Sanchez, Santiago Thibaud
The Oncologist|April 9, 2026
Comment on "How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes"Joshua Richter, Michael Davis, Yi Chai
Future Oncology (London, England)|June 9, 2020
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myelomaShambavi Richard, Joshua Richter, Sundar Jagannath
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2023
Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology CentersJoshua Richter, Stephen J Noga, Robert Rifkin
Pageof 13